SBS Genetech: Fortifying the Future of Life Sciences

Today, the pharmaceutical and life sciences industries stand at an inflection point. Exploring new frontiers of growth, these industries are witnessing significant transformations in the way they operate, while also keeping up with soaring research and development costs. The recent advances in technology, expanding markets, and increased adoption of digital technologies have set the ball rolling for pharmaceutical and life sciences industries, enabling organizations to revive their fortunes. Against this constantly developing backdrop of the pharmaceutical industry and life sciences, the demands of scientific researchers are becoming increasingly diversified, leading to the emergence of many specialized life sciences enterprises. However, the limited energy and time of scientific researchers refrain them from obtaining the comprehensive market information required to enjoy high-quality and low-cost scientific research products.

This is where SBS Genetech steps in to change the industry narrative. With an unwavering dedication to partnering with researchers, SBS Genetech was founded with a singular focus on empowering its clients with products and services that can help them in succeeding and accelerating their life sciences development initiatives. One of the earliest Chinese companies providing custom oligonucleotides synthesis, gene synthesis, and custom peptide synthesis, SBS Genetech is committed to helping the researchers complete their screening processes by directly accessing safer, higher quality and more affordable products from leading suppliers and empowering enterprises with international competitiveness to open a larger market. “We firmly believe that by providing researchers with convenient and affordable research products, life sciences can benefit the world better,” says Stephen Lan, Vice President of SBS Genetech.

With almost two decades into its inception, SBS Genetech has witnessed the lows and highs in the industry, while also experiencing the marvels that the life sciences realm has brewed over the years. Backed by this unprecedented expertise and in-depth industry knowledge, the company has been recognized as a high-quality, trusted provider of life sciences research and application services and products. Keeping up with the rapid advances, SBS Genetech has transitioned itself into an integrated data-driven platform to provide comprehensive solutions for global pharmaceutical and life sciences participants along the overall value chain.

However, no one can whistle a symphony as it takes a whole orchestra to play it. In the same vein, the company takes pride in bringing together thousands of scientific researchers together to participate in the process of promoting the development of life sciences in the 21st century—the decade for innovation.

In essence, SBS Genetech offers a broad portfolio coverage, including DNA/RNA oligonucleotide synthesis, gene synthesis, peptide synthesis, biochemical reagents, PCR-related products, RNA-related products, gene manipulation kits, and more. The uniqueness of SBS Genetech stems from its well-established sales and distribution network widespread over more than 40 countries, and its strategic cooperation with dozens of other competitive suppliers in specific areas, ensuring its heightened product quality and multifaceted pricing advantages.

At the outset, a majority of SBS Genetech’s customers used to be pharma enterprises with single and relatively stable orders, requiring the company to perform only a one-time search-work for helping the suppliers with docking. In the present day, as e-commerce is taking the business prospect to the next level with the dawn of AI technology, SBS Genetech has shifted its focus to scientific research institutions with more diversified and unstable orders. Exposure to these new technologies has enabled the company to match the most suitable suppliers in real-time. That said, SBS Genetech is currently building a comprehensive database similar to its knowledge engine based on existing suppliers. Furthermore, the company has introduced machine learning algorithms for pricing and matching to create an integrated data-driven platform for achieving real-time transactions.

With its clientele spanning 46 countries, SBS Genetech digitalizes the advantage of its widespread distribution network to not only meet the bulk needs of enterprise users but also better meet the flexible orders of research users, all while ensuring the extreme cost performance of products. The unique capabilities and delivery of quality by the company can be best illustrated with a case study wherein SBS Genetech had the privilege of assisting a provider with more than 1100 products. Analyzing with its knowledge engine and testing by experiments, SBS Genetech screened out 17 products with strong international competitiveness. The company’s existing distribution network helped the provider successfully promote their products in more than 40 countries. Additionally, with the sole reliance on just 17 products, the provider’s quarterly turnover increased by 29 percent. Furthermore, SBS Genetech has continued to work in-depth with this client to discover more potential products.

Scripting similar success stories for its clients, SBS Genetech is not the one to rest on its laurels. By building the integrated data-driven platform, SBS Genetech has no plans of slows down and envisions to help connect global participants along with the life sciences research and application services and product value chain. The company aims to enable the users to enjoy the most cost-effective products, as well as empower high-quality providers to open the market. Under the premise of guaranteeing the cost-performance ratio of products, SBS Genetech will rapidly expand its portfolio along the main business line. The company has already expanded its DNA synthesis services to cover various nucleic acid synthesis services, including siRNA synthesis, miRNA synthesis, and sgRNA synthesis, used for gene editing. “We will accelerate this process to further enhance our competitiveness by covering more scenarios in life sciences research,” concludes Lan.